GODOFREDO ROSSI: Open Payments
NPI 1225073901 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,982 in 188 payments from 39 companies in 2025. Trend: 2023 $4,327 · 2024 $3,725 · 2025 $3,982
Food & beverage: $3,946Education: $36
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 22 | $401 |
| Biogen, Inc. | 12 | $275 |
| SK Life Science, Inc. | 12 | $269 |
| Otsuka America Pharmaceutical, Inc. | 14 | $230 |
| Novo Nordisk Inc | 5 | $202 |
| ARGENX US, INC. | 6 | $199 |
| Alexion Pharmaceuticals, Inc. | 4 | $190 |
| Eisai Inc. | 4 | $183 |
| Abbott Laboratories | 10 | $180 |
| Janssen Biotech, Inc. | 6 | $167 |
Products named: KESIMPTA, REXULTI, VYVGART HYTRULO, VUMERITY, ULTOMIRIS, Leqembi, Ozempic, INFINITY.
Industry payments across TX — which companies pay providers there.
